HIV検査の世界市場予測（～2021年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 MARKET SCOPE 15
1.3.1 MARKETS COVERED 15
1.3.2 YEARS CONSIDERED FOR THE STUDY 15
1.4 CURRENCY 16
1.5 LIMITATIONS 16
1.6 STAKEHOLDERS 16

2 RESEARCH METHODOLOGY 17
2.1 SECONDARY DATA 18
2.1.1 KEY DATA FROM SECONDARY SOURCES 18
2.2 PRIMARY DATA 19
2.2.1 KEY DATA FROM PRIMARY SOURCES 20
2.3 MARKET SIZE ESTIMATION 20
2.3.1 BOTTOM-UP APPROACH 21
2.3.2 TOP-DOWN APPROACH 22
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.5 ASSUMPTIONS FOR THE STUDY 24

3 EXECUTIVE SUMMARY 25
3.1 INTRODUCTION 25
3.2 CONCLUSION 27

4 PREMIUM INSIGHTS 28
4.1 HIV DIAGNOSTICS: MARKET OVERVIEW 28
4.2 GEOGRAPHIC ANALYSIS: HIV DIAGNOSTICS MARKET, BY TEST TYPE (2016) 29
4.3 GEOGRAPHIC SNAPSHOT OF THE HIV DIAGNOSTICS MARKET 30
4.4 LIFE CYCLE ANALYSIS, BY REGION 31

5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.1.1 DRIVERS 34
5.1.1.1 Growing worldwide prevalence of HIV/AIDS 34
5.1.1.2 Increasing number of blood transfusions and blood donations 35
5.1.1.3 Benefits offered by point-of-care instruments & kits 36
5.1.1.4 Increasing government initiatives 36
 
5.1.2 RESTRAINTS 37
5.1.2.1 High cost of NAT 37
5.1.2.2 Lack of mandates for NAT in developing countries 37
5.1.3 OPPORTUNITY 38
5.1.3.1 Emerging economies offer lucrative growth opportunities for HIV diagnostics 38
5.1.4 TREND 38
5.1.4.1 Increase in use of home access kits and instruments 38

6 HIV DIAGNOSTICS MARKET, BY PRODUCT 39
6.1 INTRODUCTION 40
6.2 CONSUMABLES 42
6.2.1 ASSAYS AND KITS & REAGENTS 43
6.2.2 OTHER CONSUMABLES 44
6.3 INSTRUMENTS 45
6.4 SOFTWARE & SERVICES 46

7 HIV DIAGNOSTICS MARKET, BY TEST TYPE 47
7.1 INTRODUCTION 48
7.2 ANTIBODY TESTS 50
7.2.1 HIV-1 SCREENING TESTS 51
7.2.1.1 ELISA 52
7.2.1.2 Rapid tests 53
7.2.1.3 Home access dried blood spots 54
7.2.2 HIV-1 ANTIBODY CONFIRMATORY TESTS 54
7.2.2.1 Western blot tests 56
7.2.2.2 Indirect immunofluorescence assays (IFA) 57
7.2.2.3 Line immunoassays 57
7.2.2.4 Radio-immunoprecipitation assays 58
7.2.3 HIV-2 & GROUP O DIAGNOSTIC TESTS 59
7.3 VIRAL LOAD TESTS 60
7.4 CD4 TESTS 61
7.5 TESTS FOR EARLY INFANT DIAGNOSIS 62
7.6 TESTS FOR VIRAL IDENTIFICATION 63

8 HIV DIAGNOSTICS MARKET, BY END USER 64
8.1 INTRODUCTION 65
8.2 DIAGNOSTIC LABORATORIES 66
8.3 HOSPITALS 67
8.4 BLOOD BANKS 68
8.5 HOME CARE SETTINGS 69
8.6 OTHER END USERS 70

9 HIV DIAGNOSTICS MARKET, BY REGION 71
9.1 INTRODUCTION 72
9.2 NORTH AMERICA 74
9.2.1 U.S. 78
9.2.2 CANADA 80
9.3 EUROPE 82
9.4 ASIA 85
9.4.1 CHINA 88
9.4.2 JAPAN 90
9.4.3 INDIA 92
9.4.4 REST OF ASIA (ROA) 94
9.5 REST OF THE WORLD (ROW) 96

10 COMPETITIVE LANDSCAPE 98
10.1 INTRODUCTION 98
10.2 STRATEGIC OVERVIEW 98
10.3 MARKET SHARE ANALYSIS 99
10.4 COMPETITIVE SITUATION AND TRENDS 100
10.4.1 PRODUCT LAUNCHES 101
10.4.2 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS 101
10.4.3 EXPANSIONS 102
10.4.4 OTHER DEVELOPMENTS 103

11 COMPANY PROFILES 104
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 INTRODUCTION 104
11.2 SIEMENS HEALTHINEERS (A DIVISION OF SIEMENS AG) 105
11.3 ROCHE DIAGNOSTICS (DIVISION OF HOFFMAN LA ROCHE LTD.) 107
11.4 ABBOTT LABORATORIES 110
11.5 BECKMAN COULTER, INC. (SUBSIDIARY OF DANAHER CORPORATION) 112
11.6 THERMO-FISHER SCIENTIFIC INC. 115
11.7 MERCK KGAA 117
11.8 BECTON, DICKINSON & COMPANY 119
11.9 HOLOGIC INC. 121
11.10 ALERE INC. 123
11.11 BIO-RAD LABORATORIES 126

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
 

12 APPENDIX 129
12.1 INSIGHTS OF INDUSTRY EXPERTS 129
12.2 DISCUSSION GUIDE 130
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 132
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 134
12.5 AVAILABLE CUSTOMIZATIONS 135
12.6 RELATED REPORTS 136
12.7 AUTHOR DETAILS 137